logo-loader

Else Nutrition protein shakes for kids are #1 and #2 best-sellers on Amazon's hot new releases

Published: 08:54 24 Jun 2021 EDT

Else Nutrition Holdings Inc -
Amazon updates the rankings based on sales performance of new products

Else Nutrition Holdings Inc (CVE:BABY) (OTCMTKS:BABYF) (FRA:0YL) said its newly-launched plant-based protein shakes for kids have reached Amazon.com's top positions in hot new releases in the baby and toddler nutritional shakes category as of June 20. 

Else shakes are made from new protein recipes derived from whole organic almonds, buckwheat and tapioca, which comprise 95% of the product's composition. 

“We're thrilled to have such favorable early response by parents to our newest products in the Else portfolio,” Else Nutrition Holdings CEO Hamutal Yitzhak said in a statement. 

READ: Else Nutrition Holdings is seeing its sales momentum accelerate with its plant-based toddler foods

“As part of our mission to help change the face of early childhood nutrition, the addition of these new products allows us to offer first of its kind whole-food-based, clean label products to many more families,” Yitzhak added.

Amazon updates the rankings based on sales performance of new products.

Else Plant-Powered Complete Nutrition Shakes provide healthy fats, healthy carbs and plant-powered proteins, as well as over 20 essential nutrients to support healthy growth, filling in nutritional gaps, with 50% less sugar than leading brands.  

The product can be served as a milk alternative, meal replacement, served alongside meals, or mixed into favorite recipes.

The plant-based protein shakes, suitable for children three years of age and older, is the second product line introduced by ELSE following its original toddler plant-based nutrition formula. 

Else Nutrition is an Israel-based food and nutrition company focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula.

Contact Sean at sean@proactiveinvestors.com

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 30 minutes ago